Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
2027. jan. 6.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
2026. nov. 23.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.
2026. nov. 6.· The oncologist· PUBMED
Publikáció
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
2026. nov. 3.· Molecular cancer therapeutics· PUBMED
Publikáció
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Vizsgálat
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer.
2026. nov. 1.· The journal of pathology. Clinical research· PUBMED
Publikáció
c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy.
2026. nov. 1.· Cancer medicine· PUBMED
Publikáció
B Cell Deficiency Protects Against the Development of c-MET and Beta-Catenin Driven Hepatocellular Carcinoma in Mice.
2026. nov. 1.· Cell biology international· PUBMED
Vizsgálat
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
2026. okt. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.
2026. okt. 26.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States.
2026. okt. 15.· Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research· PUBMED
Publikáció
HIV-1 hijacks HGF/c-MET signaling to promote viral entry and replication in primary CD4+ T cells.
2026. okt. 14.· mBio· PUBMED
Publikáció
Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
2026. okt. 12.· Current oncology (Toronto, Ont.)· PUBMED
Publikáció
Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.
2026. okt. 8.· PloS one· PUBMED
Publikáció
Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.
2026. okt. 7.· The oncologist· PUBMED
Publikáció
Comparative Immunohistochemical Analysis of FAP and c-MET Expression Across Renal Cell Carcinoma Subtypes: Preliminary Results and Potential Theranostic Implications.
2026. okt. 6.· Diagnostics (Basel, Switzerland)· PUBMED
Publikáció
Reclassification of Noncanonical MET Splice-Site Variants Using RNA-Based Validation: A Practical Diagnostic Approach in Non-Small Cell Lung Cancer.
2026. okt. 2.· Turk patoloji dergisi· PUBMED
Vizsgálat
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
2026. okt. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
2026. szept. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
c-MET/NF-κB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer.
2026. szept. 30.· International immunopharmacology· PUBMED
Publikáció
Erratum: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
2026. szept. 24.· Hepatology (Baltimore, Md.)· PUBMED
Publikáció
Prognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study.
2026. szept. 24.· Frontiers in oncology· PUBMED
Publikáció
Longitudinal Assessment of EGFR and MET Transcriptional Activity Using Cell-Free Chromatin Immunoprecipitation in Two Patients with EGFR-Mutated Non-Small Cell Lung Cancer.
2026. szept. 23.· Cancers· PUBMED
Publikáció
Novel 1-benzyl-oxindole indole hybrids targeting PDGFR-β, SRC, and c-MET signaling and inducing caspase-3-dependent apoptosis in pancreatic cancer cells.
2026. szept. 17.· European journal of medicinal chemistry· PUBMED
Publikáció
Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.
2026. szept. 17.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
A Dual-Ligand PDC Co-Targeting FOLR1 and c-Met Enhances Tumor Accumulation and Antitumor Efficacy in Ovarian Cancer.
2026. szept. 17.· Cancers· PUBMED
Publikáció
Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma.
2026. szept. 16.· Oral and maxillofacial surgery· PUBMED
Publikáció
Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer.
2026. szept. 15.· Bioorganic chemistry· PUBMED
Publikáció
HGF/c-MET signaling induces glutamine metabolism in MET-amplified head and neck squamous cell carcinoma via MAPK/ERK-dependent induction of GLS-1.
2026. szept. 15.· Medical oncology (Northwood, London, England)· PUBMED